Back to Treatments

Treatment

SGLT2 Inhibitor (Dapagliflozin)

1
Conditions
14
Trials
15K
Participants
60%
Average Safety

Condition Evidence

Diabetes mellitus type 1

14 trials · 15K participants

70% effectiveness · 60% safety
SGLT2 Inhibitor (Dapagliflozin) | DFDA